Use Of Long-Acting Glp-1 Peptides
Patent No. EP3689365 (titled "Use Of Long-Acting Glp-1 Peptides") was filed by Novo Nordisk on Jun 21, 2013. The application was issued on Aug 6, 2025.
Patent Summary
Improved GLP-1 agonist therapy for type 2 diabetes and obesity, comprising once-weekly administration of semaglutide in doses of 0.4-1.6 mg, which provides superior glycemic control and weight loss compared to daily liraglutide doses. The therapy is characterized by a prolonged half-life, enhanced stability against gastrointestinal enzymes, and improved potency in stimulating GLP-1 receptor activity.
Patent Family
Patent Oppositions (5)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3689365
- Application Number
- EP20157813A
- Filing Date
- Jun 21, 2013
- Status
- Granted And Under Opposition
- Jul 4, 2025
- Publication Date
- Aug 6, 2025
- External Links
- Slate, Register , Google Patents